Connor, Clark & Lunn Investment Management (CC&L)’s Legend Biotech LEGN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	+41,384	New	+$1.12M	﹤0.01%	1143
2025 Q1	–	Sell	-7,324	Closed	-$238K	–	1521
2024 Q4	$238K	Buy	7,324 +835	+13%	+$34.6K	﹤0.01%	1295
2024 Q3	$316K	Buy	+6,489	New	+$346K	﹤0.01%	1221
2023 Q1	–	Sell	-6,596	Closed	-$329K	–	1364
2022 Q4	$329K	Sell	6,596 -17,535	-73%	-$850K	﹤0.01%	965
2022 Q3	$985K	Buy	24,131 +8,727	+57%	+$410K	0.01%	660
2022 Q2	$847K	Buy	15,404 +3,921	+34%	+$166K	0.01%	658
2022 Q1	$417K	Buy	+11,483	New	+$454K	﹤0.01%	812

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LEGN Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Legend Biotech (LEGN) in Q2 2026: 41,384 shares worth $1.2M. The stake represents ﹤0.01% of the portfolio and ranks #1143 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in LEGN as recently as Q4 2024.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LEGN in Q1 2022 and has held it in 7 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 41,384 shares of Legend Biotech worth $1.2M as of Q2 2026.
Legend Biotech was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
Legend Biotech made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1143 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Legend Biotech in Q1 2022 and has held it in 7 quarters since.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.